Kris V. Kowdley

65.1k total citations · 18 hit papers
451 papers, 29.4k citations indexed

About

Kris V. Kowdley is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Kris V. Kowdley has authored 451 papers receiving a total of 29.4k indexed citations (citations by other indexed papers that have themselves been cited), including 269 papers in Hepatology, 268 papers in Epidemiology and 97 papers in Surgery. Recurrent topics in Kris V. Kowdley's work include Liver Disease Diagnosis and Treatment (244 papers), Hepatitis C virus research (114 papers) and Liver Diseases and Immunity (99 papers). Kris V. Kowdley is often cited by papers focused on Liver Disease Diagnosis and Treatment (244 papers), Hepatitis C virus research (114 papers) and Liver Diseases and Immunity (99 papers). Kris V. Kowdley collaborates with scholars based in United States, Canada and United Kingdom. Kris V. Kowdley's co-authors include Arun J. Sanyal, David E. Kleiner, Brent A. Neuschwander‐Tetri, Elizabeth M. Brunt, Naga Chalasani, Mark L. Van Natta, Joel E. Lavine, Arthur J. McCullough, Jeanne M. Clark and Anna Mae Diehl and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Kris V. Kowdley

432 papers receiving 28.6k citations

Hit Papers

Pioglitazone, Vitamin E, ... 2004 2026 2011 2018 2010 2014 2014 2021 2014 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
    2010 2.5k citations Arun J. Sanyal, Kris V. Kowdley et al. profile →
  2. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
    2014 1.7k citations Brent A. Neuschwander‐Tetri, Rohit Loomba et al. profile →
  3. Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
    2014 686 citations Kris V. Kowdley et al. profile →
  4. Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
    2021 646 citations Arun J. Sanyal, Brent A. Neuschwander‐Tetri et al. profile →
  5. ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
    2014 646 citations Kris V. Kowdley, Kosh Agarwal et al. profile →
  6. Endpoints and clinical trial design for nonalcoholic steatohepatitis
    2011 586 citations Arun J. Sanyal, Kris V. Kowdley et al. Hepatology profile →
  7. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
    2004 545 citations Keith D. Lindor, Kris V. Kowdley et al. Hepatology profile →
  8. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis #
    2009 478 citations Keith D. Lindor, Kris V. Kowdley et al. Hepatology profile →
  9. Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease
    2018 452 citations Kris V. Kowdley, Brent A. Neuschwander‐Tetri et al. profile →
  10. Diagnosis and management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
    2011 428 citations Kris V. Kowdley et al. Hepatology profile →
  11. Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid
    2014 421 citations Gideon M. Hirschfield, Andrew L. Mason et al. Gastroenterology profile →
  12. Serum Ferritin Is An Independent Predictor of Histologic Severity and Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    2011 412 citations Kris V. Kowdley, Brent A. Neuschwander‐Tetri et al. Hepatology profile →
  13. ACG Clinical Guideline: Primary Sclerosing Cholangitis
    2015 331 citations Keith D. Lindor, Kris V. Kowdley et al. profile →
  14. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
    2020 280 citations Vlad Ratziu, Arun J. Sanyal et al. Hepatology profile →
  15. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
    2023 271 citations Rohit Loomba, Arun J. Sanyal et al. profile →
  16. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
    2019 270 citations Brent A. Neuschwander‐Tetri, Kris V. Kowdley et al. profile →
  17. Saroglitazar, a PPAR‐α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double‐Blind Phase 2 Trial
    2021 261 citations Mazen Noureddin, Kris V. Kowdley et al. Hepatology profile →
  18. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
    2019 205 citations Michael Trauner, Aliya Gulamhusein et al. Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kris V. Kowdley United States 86 20.1k 14.5k 5.6k 5.1k 3.2k 451 29.4k
Giovanni Targher Italy 103 29.3k 1.5× 8.9k 0.6× 6.3k 1.1× 17.7k 3.4× 5.4k 1.7× 563 44.7k
Elizabeth M. Brunt United States 81 39.0k 1.9× 17.5k 1.2× 8.9k 1.6× 15.6k 3.0× 8.2k 2.6× 273 50.2k
Naga Chalasani United States 85 26.8k 1.3× 14.3k 1.0× 6.7k 1.2× 10.1k 2.0× 4.1k 1.3× 495 37.2k
Bruce R. Bacon United States 66 12.7k 0.6× 10.4k 0.7× 2.0k 0.4× 2.2k 0.4× 1.9k 0.6× 284 21.7k
Elisabetta Bugianesi Italy 77 27.9k 1.4× 10.6k 0.7× 4.4k 0.8× 12.9k 2.5× 5.4k 1.7× 298 33.3k
Michael Trauner Austria 100 18.4k 0.9× 14.9k 1.0× 12.0k 2.1× 2.7k 0.5× 6.8k 2.1× 867 39.1k
Christopher P. Day United Kingdom 86 23.0k 1.1× 10.2k 0.7× 3.7k 0.7× 9.9k 1.9× 4.1k 1.3× 186 31.1k
Stephen H. Caldwell United States 63 14.5k 0.7× 10.3k 0.7× 4.3k 0.8× 4.2k 0.8× 1.9k 0.6× 259 19.1k
Andrew K. Burroughs United Kingdom 93 24.1k 1.2× 29.5k 2.0× 13.2k 2.4× 889 0.2× 2.2k 0.7× 506 38.8k
Arthur J. McCullough United States 73 28.2k 1.4× 12.0k 0.8× 6.0k 1.1× 12.0k 2.3× 5.5k 1.7× 293 35.4k

Countries citing papers authored by Kris V. Kowdley

Since Specialization
Citations

This map shows the geographic impact of Kris V. Kowdley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris V. Kowdley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris V. Kowdley more than expected).

Fields of papers citing papers by Kris V. Kowdley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris V. Kowdley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris V. Kowdley. The network helps show where Kris V. Kowdley may publish in the future.

Co-authorship network of co-authors of Kris V. Kowdley

This figure shows the co-authorship network connecting the top 25 collaborators of Kris V. Kowdley. A scholar is included among the top collaborators of Kris V. Kowdley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kris V. Kowdley. Kris V. Kowdley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bowlus, Christopher L., Cynthia Levy, Kris V. Kowdley, et al.. (2025). Development of the natural history component of an early economic model for primary sclerosing cholangitis. Orphanet Journal of Rare Diseases. 20(1). 133–133.
2.
Sanyal, Arun J., Kris V. Kowdley, Nancy Reau, et al.. (2024). Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. Hepatology Communications. 8(6). 6 indexed citations
3.
Harrison, Stephen A., Vlad Ratziu, Quentin M. Anstee, et al.. (2023). Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 59(1). 51–63. 56 indexed citations
4.
5.
Ratziu, Vlad, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology. 76(3). 506–517. 87 indexed citations
6.
Schattenberg, Jörn M., Albert Parés, Kris V. Kowdley, et al.. (2021). A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology. 74(6). 1344–1354. 125 indexed citations
7.
Younossi, Zobair M., Maria Stepanova, Mazen Noureddin, et al.. (2021). Improvements of Fibrosis and Disease Activity Are Associated With Improvement of Patient‐Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. Hepatology Communications. 5(7). 1201–1211. 24 indexed citations
8.
Trauner, Michael, Aliya Gulamhusein, Bilal Hameed, et al.. (2019). The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC.. Hepatology. 3 indexed citations
9.
Sawangjit, Ratree, Bunchai Chongmelaxme, Pochamana Phisalprapa, et al.. (2016). Comparative efficacy of interventions on nonalcoholic fatty liver disease (NAFLD). Medicine. 95(32). e4529–e4529. 50 indexed citations
10.
Risques, Rosa Ana, Lisa A. Lai, Çiğdem Himmetoğlu, et al.. (2011). Ulcerative Colitis–Associated Colorectal Cancer Arises in a Field of Short Telomeres, Senescence, and Inflammation. Cancer Research. 71(5). 1669–1679. 118 indexed citations
11.
Kowdley, Kris V., Velimir A. Luketic, Robert Chapman, et al.. (2011). 28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC. Journal of Hepatology. 54. S13–S13. 47 indexed citations
12.
Alexander, Jacob & Kris V. Kowdley. (2009). HFE-associated hereditary hemochromatosis. Genetics in Medicine. 11(5). 307–313. 81 indexed citations
13.
Alexander, Jacob & Kris V. Kowdley. (2006). Epidemiology of hepatitis B--clinical implications.. PubMed Central. 8(2). 13–13. 14 indexed citations
14.
Chutkan, Robynne, Jonathan Cohen, Marcia Cruz–Correa, et al.. (2004). Training guideline for use of propofol in gastrointestinal endoscopy. Gastrointestinal Endoscopy. 60(2). 167–172. 92 indexed citations
15.
Farivar, Alexander S., Eric Vallières, Kris V. Kowdley, Douglas E. Wood, & Michael S. Mulligan. (2004). Airway obstruction complicating esophageal stent placement in two post-pneumonectomy patients. The Annals of Thoracic Surgery. 78(2). e22–e23. 12 indexed citations
16.
Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations
17.
Kowdley, Kris V., Bruce M. Coull, & Eric Orwoll. (1999). Cognitive Impairment and Intracranial Calcification in Chronic Hypoparathyroidism. The American Journal of the Medical Sciences. 317(5). 273–273. 30 indexed citations
18.
Saltzman, John R., Kris V. Kowdley, Gayle Perrone, & Robert M. Russell. (1995). Changes in Small‐Intestine Permeability with Aging. Journal of the American Geriatrics Society. 43(2). 160–164. 71 indexed citations
19.
Provenzale, Dawn, Kris V. Kowdley, Sanjeev Arora, & John B. Wong. (1995). Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology. 109(4). 1188–1196. 74 indexed citations
20.
Glickerman, David J., Kris V. Kowdley, & Josef Rösch. (1988). Urokinase in gastrointestinal tract bleeding.. Radiology. 168(2). 375–376. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giovanni Targher Breakdown of academic impact, for papers by Elizabeth M. Brunt Breakdown of academic impact, for papers by Naga Chalasani Breakdown of academic impact, for papers by Bruce R. Bacon Breakdown of academic impact, for papers by Elisabetta Bugianesi Breakdown of academic impact, for papers by Michael Trauner Breakdown of academic impact, for papers by Christopher P. Day Breakdown of academic impact, for papers by Stephen H. Caldwell Breakdown of academic impact, for papers by Andrew K. Burroughs Breakdown of academic impact, for papers by Arthur J. McCullough
Rankless by CCL
2026